Nirsevimab
Respiratory Syncytial Virus Infectious Disease
Explore 2 assets in Respiratory Syncytial Virus Infectious Disease →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Menzies School of Health Research
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07578298CT.gov THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Respiratory Syncytial Virus Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nirsevimab (this asset) | Menzies School of Health Research | Approved | BB · 65 |
| Recombinant Respiratory Syncytial Virus Pre-Fusion F Protein Antigen | Medical University of Vienna | P2 | CCC |
Other indications for Nirsevimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Viral Respiratory Tract Infection | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nirsevimab in Respiratory Syncytial Virus Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nirsevimab-respiratory-syncytial-virus-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →